#EHA2024 Data: Wugen presents positive Phase 2 results for WU-CART-007. During today’s oral presentation at the European Hematology Association (EHA) 2024 Hybrid Congress, researchers shared positive Phase 2 results for our investigational allogeneic, off-the-shelf anti-CD7 CAR-T therapy in patients with relapsed/refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Learn more about what these WU-CART-007 findings could mean for patients with hard-to-treat blood cancers: https://bit.ly/4aXdRi4 #celltherapy #research #biotechnology #WashU
Wugen
Biotechnology Research
St. Louis, Missouri 4,192 followers
Engineering the Next Generation of Off-the-Shelf Cell Therapies
About us
Wugen is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. Wugen is based out of St. Louis, Missouri and San Diego, California.
- Website
-
http://www.wugen.com
External link for Wugen
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- St. Louis, Missouri
- Type
- Privately Held
- Founded
- 2018
Locations
-
Primary
4260 Forest Park Ave
Suite 100
St. Louis, Missouri 63108, US
-
10210 Campus Point Dr
150
San Diego, California 92121, US
Employees at Wugen
Updates
-
Wugen reposted this
BIOTECH NEWS: Wugen announced RMAT and PRIME designations to accelerate regulatory reviews for its investigational, off-the-shelf allogeneic CAR-T cell therapy, WU-CART-007, in the U.S and E.U. These designations follow FDA and EMA review of Wugen studies, including its global Phase 1/2 study. The newest Phase 2 data will be presented at European Hematology Association (EHA)'s 2024 meeting in June. Learn more about todays’ news and WU-CART-007: https://bit.ly/3wPuRIX #EHA2024 #cancer #celltherapy
-
BIOTECH NEWS: Wugen announced RMAT and PRIME designations to accelerate regulatory reviews for its investigational, off-the-shelf allogeneic CAR-T cell therapy, WU-CART-007, in the U.S and E.U. These designations follow FDA and EMA review of Wugen studies, including its global Phase 1/2 study. The newest Phase 2 data will be presented at European Hematology Association (EHA)'s 2024 meeting in June. Learn more about todays’ news and WU-CART-007: https://bit.ly/3wPuRIX #EHA2024 #cancer #celltherapy
-
We’re hiring! Wugen is seeking an exceptional and highly motivated candidate to join our growing QA team based in St. Louis, MO or San Diego, CA. The person in this role will be responsible for helping maintain Wugen's quality systems through electronic document management. Learn more: https://lnkd.in/df2XrytM
-
Thrilled to announce our new agreement with Cellipont Bioservices, a leading cell therapy contract development and manufacturing organization (CDMO), for the manufacturing of Wugen’s allogeneic CAR-T cell therapies being studied for hematological and solid tumor malignancies. #oncology #cancerresearch #biotechnology
PRESS RELEASE: Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies. We're pleased to be joining forces with Wugen Click here to view the full release: https://lnkd.in/eDhduT7g #CellTherapy #CAR-T #CancerResearch #Innovation #Partnership #Biotech #Healthcare #CDMO #TheWoodlands
Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies | Cellipont Bioservices
https://cellipont.com
-
Today, we had the privilege of sharing the latest data from our ongoing Phase 1/2 trial of WU-CART-007 at the American Society of Hematology Annual Meeting & Exposition. #ASH23 Initial favorable results underscore our ongoing progress in advancing Wugen’s mission to leverage cutting-edge CAR-T therapies for difficult-to-treat blood cancers. Learn more about the latest data on WU-CART-007 here: https://bit.ly/3tnauB8 #clinicaltrials #immunotherapy #oncology #biotechnology
Wugen Presents Latest Data from First-In-Human Phase 1/2 Trial of WU-CART-007 in Patients with Difficult-to-Treat Blood Cancers at American Society of Hematology Annual Meeting | Wugen
https://wugen.com
-
We are excited to join hematology experts at the American Society of Hematology Annual Meeting & Exposition to share our newest data on potential new treatments for hard-to-treat blood cancers. #ASH23 We’re presenting oral and poster sessions about data from our two investigational allogeneic cell therapies for challenging hematologic cancers – explore the details in our curtain raiser release: https://lnkd.in/gPmE9eaR #biotechnology #celltherapy #immunotherapy #oncology
-
Today, we unveiled four new abstracts from new clinical and preclinical studies to be presented at the 65th American Society of Hematology Annual Meeting & Exposition. Clinical data presented will highlight the latest findings on WU-CART-007 in patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T ALL)/lymphoblastic lymphoma (LBL). In addition, results from three pre-clinical studies of WU-NK-101, an allogeneic memory natural killer (NK) cell therapy, in patients with acute myeloid #leukemia (#AML) will be presented. Read our announcement to learn more: https://lnkd.in/gPmE9eaR #ASH23 #oncology #cancerresearch #biotechnology
-
We're looking forward to the Society for Immunotherapy of Cancer (SITC) Annual Meeting, where we'll share new preclinical data for WU-NK-101, an allogenic memory NK cell product demonstrating engagement of the adaptive immune response and synergy with checkpoint inhibitors to overcome immune evasion by solid tumors. These data provide a strong rationale for exploring the combination of WU-NK-101 with immune checkpoint inhibitors to improve patient outcomes. #SITC23 #onology #biotechnology #cancerresearch
-